Obviously they're going to "break records" and exceed expectations again with 55,600 prescriptions filled and 4.85M in Rx revs. But I'm real curious to see how the construction and permit expenses will factor in to Q3 results.
Factoring in the quarter should leave them only $2.75M short of that $16M target for the full year. $17.5M seems more likely.
When October's numbers come out, if they post 20k prescriptions and 1.7M in Rx revenue, it would put $18M for 2016 within reach.
The size of the Chicago Venture note sketches me out. They need to keep putting up double-digit prescription growth.
Edit: oops. Didn't mean to post this as a reply to your post. Been awhile since I've been on Ihub. Sorry about that!